MedTrace Logo

Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory

NCT04630327 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 226

Last updated 2022-06-21

No results posted yet for this study

Summary

Depression and anxiety in female patients with cancer are serious comorbidities that affect the quality of life for patients and their survival rates as they have poorer health outcomes. This validation study is a part of the study on the prevalence of depression and anxiety among breast cancer patients. This study aims to investigate the validity of the Kazakh and Russian versions of the Beck Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI) among female cancer patients in Almaty, Kazakhstan.

Conditions

Interventions

OTHER

Beck Depression Inventory-21 (diagnostic survey)

Kazakh or Russian versions of the Beck Depression Inventory-21will be filled by female cancer patients

OTHER

Beck Anxiety Inventory

Kazakh or Russian versions of the Beck Anxiety Inventory will be filled by female cancer patients

OTHER

Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria

Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria as a gold standard of diagnosing depression or anxiety

Sponsors & Collaborators

  • Kazakh Medical University of Continuing Education

    lead OTHER

Principal Investigators

  • Botagoz Turdaliyeva, Professor · Kazakh Medical University of Continuing Education

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-13
Primary Completion
2022-04-28
Completion
2022-05-01

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04630327 on ClinicalTrials.gov